Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer

por Yap, Timothy A, Popat, Sanjay
Publicado 2014

Development of Molecularly Driven Targeted Combination Strategies

por Yap, Timothy A., Rodon, Jordi
Publicado 2017

Combination drug development in BRAF mutant colorectal cancer

por Lam, Michael, Pant, Shubham, Yap, Timothy A.
Publicado 2018

Personalization of prostate cancer prevention and therapy: are clinically qualified biomarkers in the horizon?

por Yap, Timothy A, Swanton, Charles, de Bono, Johann S
Publicado 2012

Strategies for modern biomarker and drug development in oncology

por Smith, Alan D, Roda, Desam, Yap, Timothy A
Publicado 2014

PARP inhibitors: the race is on

por Brown, Jessica S, Kaye, Stan B, Yap, Timothy A
Publicado 2016

Precision Medicine for Molecularly Targeted Agents and Immunotherapies in Early-Phase Clinical Trials

por Lopez, Juanita, Harris, Sam, Roda, Desam, Yap, Timothy A
Publicado 2015

Global Implementation of Precision Oncology

por Yam, Clinton, Ma, Brigette B. Y., Yap, Timothy A.
Publicado 2021

Targeting the PI3K-AKT-mTOR signaling network in cancer

por Khan, Khurum H., Yap, Timothy A., Yan, Li, Cunningham, David
Publicado 2013

Drugging PI3K in cancer: refining targets and therapeutic strategies

por Yap, Timothy A, Bjerke, Lynn, Clarke, Paul A, Workman, Paul
Publicado 2015

Immuno-oncology combinations: raising the tail of the survival curve

por Harris, Samuel J., Brown, Jessica, Lopez, Juanita, Yap, Timothy A.
Publicado 2016

The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage response

por Coleman, Niamh, Zhang, Bingnan, Byers, Lauren A., Yap, Timothy A.
Publicado 2020

PARP inhibitors: enhancing efficacy through rational combinations

por Bhamidipati, Deepak, Haro-Silerio, Jaime I., Yap, Timothy A., Ngoi, Natalie
Publicado 2023

Combining targeted therapeutics in the era of precision medicine

por Papadatos-Pastos, D, De Miguel Luken, M J, Yap, Timothy A
Publicado 2015

Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer

por Sundar, Raghav, Chénard-Poirier, Maxime, Collins, Dearbhaile Catherine, Yap, Timothy A.
Publicado 2017

Clinical Development of AKT Inhibitors and Associated Predictive Biomarkers to Guide Patient Treatment in Cancer Medicine

por Coleman, Niamh, Moyers, Justin T, Harbery, Alice, Vivanco, Igor, Yap, Timothy A
Publicado 2021

Antibody-drug conjugates in lung cancer: dawn of a new era?

por Coleman, Niamh, Yap, Timothy A., Heymach, John V., Meric-Bernstam, Funda, Le, Xiuning
Publicado 2023

Application of Real-World Data to External Control Groups in Oncology Clinical Trial Drug Development

por Yap, Timothy A., Jacobs, Ira, Baumfeld Andre, Elodie, Lee, Lauren J., Beaupre, Darrin, Azoulay, Laurent
Publicado 2022

Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines

por Yap, Timothy A., Ashok, Arya, Stoll, Jessica, Mauer, Elizabeth, Nepomuceno, Vanessa M., Blackwell, Kimberly L., Garber, Judy E., Meric-Bernstam, Funda
Publicado 2022

Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours

por Shapiro, Geoffrey I., Wesolowski, Robert, Devoe, Craig, Lord, Simon, Pollard, John, Hendriks, Bart S., Falk, Martin, Diaz-Padilla, Ivan, Plummer, Ruth, Yap, Timothy A.
Publicado 2021